GOG-0186K

Terminated

Return to Protocol Table

A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Principal Investigator

Ursula Matulonis

Status

Terminated

Open to Accrual

November 6, 2012

Closed to Accrual

November 6, 2012

Closed to Accrual

May 5, 2014

Closed to Accrual & Treatment

November 9, 2015

Complete

February 9, 2019

Terminated

February 9, 2019


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the activity of cabozantinib relative to weekly paclitaxel in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer with a log-rank test assessing progression-free survival (PFS) at 3.68 months (approximately pre-cycle 5) and 7.36 months (approximately pre-cycle 9). 

Patient Population

Patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer with a log-rank test assessing progression-free survival (PFS) at 3.68 months (approximately pre-cycle 5) and 7.36 months (approximately pre-cycle 9). 

Target Accrual

102

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.